title: Efficacy and tolerability of Estraderm MX, a new estradiol matrix patch.
abstract: OBJECTIVE
  To assess the efficacy and tolerability of a new matrix patch delivering 0.05 mg estradiol per day (Estraderm MX 50) in postmenopausal women with moderate to severe postmenopausal symptoms.
  
  
  METHODS
  A multicenter, double-blind, randomized, between-patient, placebo controlled trial in 109 postmenopausal women was carried out. Patches were applied twice weekly for 12 weeks. Patients were assessed at 4, 8 and 12 weeks of treatment. The primary efficacy variable was change from baseline in mean number of moderate to severe hot flushes (including night sweats) per 24 h during the last 2 weeks of treatment. Other variables included Kupperman Index, local and systemic tolerability. Plasma concentrations of estradiol (E2), estrone (E1) and estrone sulfate (E1S) were determined before and after treatment.
  
  
  RESULTS
  Estraderm MX was significantly superior to placebo (P < 0.001) in reducing mean number of moderate to severe hot flushes (including night sweats) per 24 h after 4, 8 and 12 weeks of treatment. The estimate of treatment group differences after 12 weeks was 4.2 hot flushes (95% confidence interval: 2.6-5.8). Estraderm MX also significantly reduced Kupperman Index at all time points compared to placebo (P < 0.001). Estraderm MX induced increases in mean E2, E1 and E1S plasma levels as expected (E2: baseline 2.7 pg/ml, 12 weeks 38.9 pg/ml; E1: baseline 18.8 pg/ml, 12 weeks 41.6 pg/ml; E1S: baseline 235.6 pg/ml, 12 weeks 765.1 pg/ml). Overall rates of adverse experiences were similar for Estraderm MX and placebo. The number of patients reporting skin irritation was low and similar in both groups.
  
  
  CONCLUSIONS
  Estraderm MX 50, a new matrix patch, offers an effective and well tolerated dosage form for transdermal delivery of 0.05 mg E2 per day.
authors.affiliation: Clinica Ostetrico-Ginecologica, Università di Parma, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Bacchi-Modena
authors.forename: P
authors.initials: P
authors.lastname: Bolis
authors.forename: C
authors.initials: C
authors.lastname: Campagnoli
authors.forename: F
authors.initials: F
authors.lastname: De Cicco
authors.forename: M
authors.initials: M
authors.lastname: Meschia
authors.forename: F
authors.initials: F
authors.lastname: Pansini
authors.forename: R
authors.initials: R
authors.lastname: Pisati
authors.forename: G
authors.initials: G
authors.lastname: Hüls
mesh_terms: D000279:Administration, Cutaneous; D002979:Climacteric / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004958:Estradiol / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D015914:Estrogen Replacement Therapy; D004970:Estrone / Q000031:analogs & derivatives / Q000097:blood; D005260:Female; D006801:Humans; D007558:Italy; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D004970:Estrone; D004958:Estradiol; C017296:estrone sulfate